ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
118.20
-2.37 (-1.96%)
At close: Aug 20, 2026, 4:00 PM EDT
118.62
+0.43 (0.36%)
Pre-market: Aug 21, 2026, 8:27 AM EDT
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.34M EUR in the quarter ending March 31, 2026, with 35.21% growth. This brings the company's revenue in the last twelve months to 4.92M, down -59.82% year-over-year. In the year 2025, ABIVAX Société Anonyme had annual revenue of 4.57M, down -63.22%.
Revenue (ttm)
4.92M EUR
Revenue Growth
-59.82%
P/S Ratio
1,930.15
Revenue / Employee
61,500 EUR
Employees
80
Market Cap
10.95B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.57M | -7.86M | -63.22% |
| Dec 31, 2024 | 12.43M | 7.85M | 171.67% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bio-Techne | 1.22B |
| Ionis Pharmaceuticals | 874.09M |
| Axsome Therapeutics | 776.57M |
| Krystal Biotech | 440.48M |
| Protagonist Therapeutics | 281.99M |
| Kymera Therapeutics | 105.00M |
| Cytokinetics | 67.67M |
| Praxis Precision Medicines | 7.46M |
ABVX News
- 20 days ago - AbbVie Q2 Earnings Call Highlights - Nasdaq
- 21 days ago - Abivax (ABVX) Advances Toward NDA Filing Amid Mixed Market Signals - GuruFocus
- 21 days ago - Abivax announces positive pre-NDA interaction with FDA for obefazimod in UC - TheFly
- 27 days ago - Abivax price target raised to $180 from $132 at Morgan Stanley - TheFly
- 5 weeks ago - Abivax Secures Funding to Advance Ulcerative Colitis Drug (ABVX) - GuruFocus
- 6 weeks ago - Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC - CNBC
- 6 weeks ago - Best defense is the offence, says Abivax CEO after takeover speculation - CNBC
- 6 weeks ago - ABIVAX Société Anonyme Slides: Corporate presentation - Filings